Breaking Finance News

BTIG Research disclosed Juno Therapeutics Inc (NDAQ:JUNO), bumping down its price target to $23.00 earlier today

Having a price of $22.50, Juno Therapeutics Inc (NDAQ:JUNO) traded -0.44% lower on the day. With the last stock price down 43.54% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.03% over the same period. JUNO has recorded a 50-day average of $42.03 and a two hundred day average of $29.96. Trade Volume was down over the average, with 1,123,483 shares of JUNO changing hands under the typical 2,640,200

Reporting a potential upside of 0.02%, BTIG Research dropped the price target of Juno Therapeutics Inc (NDAQ:JUNO) to $23.00

On 5/9/2017, Morgan Stanley released a statement about Juno Therapeutics Inc (NDAQ:JUNO) dropped the target price from $27.00 to $26.00 that suggested an upside of 0.12%.

Recent Performance Chart

Juno Therapeutics Inc (NDAQ:JUNO)

Juno Therapeutics Inc has with a one year low of $17.52 and a one year high of $47.03 and has a market capitalization of $0.

A total of 11 brokerages have issued a ratings update on Juno Therapeutics Inc. zero brokerages rating the company a strong buy, zero brokerages rating the company a buy, zero brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $55.73.

General Company Details For Juno Therapeutics Inc (NDAQ:JUNO)

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.